Forskning
Udskriv Udskriv
Switch language
Region Hovedstaden - en del af Københavns Universitetshospital
Udgivet

Will novel oral formulations change the management of inflammatory bowel disease?

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  1. Mometasone furoate nasal spray for the treatment of asthma

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  2. Lixisenatide for type 2 diabetes mellitus

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  3. Serotonin 2A receptor antagonists for treatment of schizophrenia

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  4. Inhibition of dipeptidyl peptidase 4 by BI-1356, a new drug for the treatment of beta-cell failure in type 2 diabetes

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

Vis graf over relationer

INTRODUCTION: The traditional management of inflammatory bowel disease (IBD) with sulphasalazine/5-aminosalicylic acid, glucocorticoids and immunomodulators (i.e., thiopurines and methotrexate) was nearly two decades ago extended with intravenously or subcutaneously administered biologics (i.e., tumor necrosis factor inhibitors and later gut-selective integrin antagonists). However, recently, orally administered treatments with simple, well-characterized, and stable structures consisting of either small molecules or anti-sense therapy have been devised.

AREAS COVERED: This review discusses the current approaches with promising new oral drugs with distinct modes of action, including: the Janus kinase inhibitors (i.e., tofacitinib, filgotinib and peficitinib); the immunomodulatory drug (laquinimod); a small α4 antagonist (AJM300); agonists for sphingosine-phosphate receptors (i.e., ozanimod, APD334, and amiselimod), as well as anti-sense therapy (mongersen) targeting SMAD7, drugs which directly target intracellular pathways of relevance for intestinal inflammation.

EXPERT OPINION: A new avenue using easily administered oral therapies for the management of IBD is being introduced. While their place in the clinical armamentarium remains to be proven, it is likely that many of these drugs will find their place in the treatment algorithm of IBD in the next few years. Thus, we will face times in which IBD therapy will be based on significantly more tablets than prescribed today.

OriginalsprogEngelsk
TidsskriftExpert Opinion on Investigational Drugs
Vol/bind25
Udgave nummer6
Sider (fra-til)709-18
Antal sider10
ISSN1354-3784
DOI
StatusUdgivet - jun. 2016

ID: 46493739